MannKind Corp NNFN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €2.65
- Day Range
- €2.81–2.81
- 52-Week Range
- —–—
- Bid/Ask
- €2.80 / €2.88
- Shares Outstanding
- 321.54M
- Market Cap
- €902.25M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 46.57
- Price/Sales
- 2.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 592
- Website
- https://www.mannkindcorp.com
Valuation
|
Metric
|
NNFN
|
|---|---|
Price/Earnings (Normalized) | 46.57 |
Price/Book Value | — |
Price/Sales | 2.58 |
Price/Cash Flow | 39.37 |
Price/Earnings
NNFN
Financial Strength
|
Metric
|
NNFN
|
|---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.72 |
Interest Coverage | −0.15 |
Quick Ratio
NNFN
Profitability
|
Metric
|
NNFN
|
|---|---|
Return on Assets (Normalized) | 2.71% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 29.56% |
Return on Assets
NNFN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TrGk$X | LOCK|?$tk | $129B | |||
| Moderna Inc
MRNA
| LOCK|j?!N^? | LOCK|@RZ | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|w%cfy# | LOCK|<@Bvv | $82B | |||
| argenx SE ADR
ARGX
| LOCK|jh^nn> | LOCK|Vs | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|c>$?z&d | LOCK|&& | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l%#&fNJ | LOCK|P!<<? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$?@k#Vwd | LOCK|ytN% | $27B | |||
| Incyte Corp
INCY
| LOCK|>NQ@GB | LOCK|Cz | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|z<zNGxK | LOCK|rF | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|y!y>>@< | LOCK|!Qq | $14B |
United States